About ArQule
Mission and Core Skills
Our mission as a biotechnology company is to research, develop, and commercialize broadly effective cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. Our complementary strengths in molecular biology and chemistry technology are driving the discovery and development of a next generation of broad-spectrum, small molecule drugs to treat human cancers. We maintain a strong commitment to basic research, and the programs in our pipeline are the direct result of our internal discovery efforts.
Cancer is the result of a range of complex genetic mutations and abnormal physiological processes that take place within the body, beginning in cells. Our molecular biology expertise enables us to understand and to affect certain key mechanisms that are common across numerous cancers and thus to halt tumor formation and progression. Our chemistry capabilities make it possible for us to imbue our products with pre-selected, drug-like characteristics and a high degree of specificity for cancer cells. We believe that these qualities, when present from the earliest stages of product development, increase the likelihood of generating safe, effective and marketable drugs.
Clinical Programs and Pipeline
We are bringing our biology and chemistry capabilities to bear upon a number of targets that are believed to contribute to the development of human cancer. Please see our Pipeline page under Research and Development for the products in our portfolio.